These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37957158)

  • 41. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
    Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Neumann T; Schneidewind L; Niederwieser D; Dölken G; Schmidt CA
    Ann Hematol; 2021 Jun; 100(6):1569-1577. PubMed ID: 33829299
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinicopathological Features of Ocular Adnexal Mantle-Cell Lymphoma in an International Multicenter Cohort.
    Knudsen MKH; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Khong JJ; McKelvie PA; Mulay K; Ralfkiaer E; Sjö LD; Vemuganti GK; Thuro BA; Curtin J; Heegaard S
    JAMA Ophthalmol; 2017 Dec; 135(12):1367-1374. PubMed ID: 29121219
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.
    Zhang Y; Liu P; Cai J; Jing H; Zou L; Huang H; Wu Y; Li W; Zhong L; Jin X; Ye X; Feng R; Zhang H; Zhang L; Lin L; Sun X; Tian Y; Xia Z; Li Z; Huang H; Xia Y; Cai Q
    Cancer Med; 2022 Nov; 11(22):4134-4145. PubMed ID: 35438258
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent advances in the management of mantle cell lymphoma.
    Rivera-Rodriguez N; Cabanillas F
    Curr Opin Oncol; 2013 Nov; 25(6):716-21. PubMed ID: 24076580
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience.
    García-Noblejas A; Martínez Chamorro C; Navarro Matilla B; Da Silva Rodriguez C; González-Lopez TJ; Oña Navarrete R; Ramírez Sánchez MJ; Martínez Barranco P; Sánchez Blanco JJ; Nicolás C; Pérez R; Sánchez González B; Ruedas López AM; Domingo-Domenech E; Panizo C; Macia S; Fernández-Fonseca E; Cannata-Ortiz J; Arranz R
    Ann Hematol; 2014 Sep; 93(9):1551-8. PubMed ID: 24782117
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma.
    Gopalsamy SN; Rosenthal KM; Ayers AA; Goy A; Leonard JP; Vose JM; Obholz KL; Armitage JO; Flowers CR
    Leuk Lymphoma; 2019 Sep; 60(9):2255-2263. PubMed ID: 30848966
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
    Hoster E; Klapper W; Hermine O; Kluin-Nelemans HC; Walewski J; van Hoof A; Trneny M; Geisler CH; Di Raimondo F; Szymczyk M; Stilgenbauer S; Thieblemont C; Hallek M; Forstpointner R; Pott C; Ribrag V; Doorduijn J; Hiddemann W; Dreyling MH; Unterhalt M
    J Clin Oncol; 2014 May; 32(13):1338-46. PubMed ID: 24687837
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
    Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
    Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.
    Schulz H; Bohlius J; Skoetz N; Trelle S; Kober T; Reiser M; Dreyling M; Herold M; Schwarzer G; Hallek M; Engert A
    Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD003805. PubMed ID: 17943799
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
    Till BG
    Curr Treat Options Oncol; 2018 Jul; 19(9):45. PubMed ID: 30032463
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
    Till BG; Li H; Bernstein SH; Fisher RI; Burack WR; Rimsza LM; Floyd JD; DaSilva MA; Moore DF; Pozdnyakova O; Smith SM; LeBlanc M; Friedberg JW
    Br J Haematol; 2016 Jan; 172(2):208-18. PubMed ID: 26492567
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
    Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
    Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
    Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma.
    Romancik JT; Gerber DG; Zhuang T; Cohen JB
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):557-565. PubMed ID: 35123927
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study.
    Ghosh N; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Huang Q
    Clin Ther; 2021 Aug; 43(8):1285-1299. PubMed ID: 34332789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?
    Yamshon S; Martin P
    Clin Adv Hematol Oncol; 2021 Jun; 19(6):376-382. PubMed ID: 34106911
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era.
    Mussetti A; Devlin SM; Castro-Malaspina HR; Barker JN; Giralt SA; Zelenetz AD; Sauter CS; Perales MA
    Bone Marrow Transplant; 2015 Oct; 50(10):1293-1298. PubMed ID: 26146802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma.
    Obrador-Hevia A; Serra-Sitjar M; Rodríguez J; Belayachi L; Bento L; García-Recio M; Sánchez JM; Villalonga P; Gutiérrez A; Fernández de Mattos S
    Br J Haematol; 2016 Sep; 174(6):899-910. PubMed ID: 27220900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.